

**OUR MISSION IS TO  
OVERCOME THIS INTRACTABLE DISEASE -TGCV**




**THE 3rd INTERNATIONAL SYMPOSIUM on  
Triglyceride Deposit Cardiomyovascuopathy  
&  
Neutral Lipid Storage Disease**

# **PROGRAM & ABSTRACTS**

**DATE:** March 14, 2015

**VENUE:** TKP Garden City Shinagawa

**PRESIDENT:** Ken-ichi Hirano Osaka University



\* These photos were kindly provided from Dr. Michio Tanaka.



THE 3rd INTERNATIONAL SYMPOSIUM on  
**Triglyceride Deposit Cardiomyovascuopathy**  
**Neutral Lipid Storage Disease** &

# **PROGRAM & ABSTRACTS**

**DATE:** March 14, 2015

**VENUE:** TKP Garden City Shinagawa

**PRESIDENT:** Ken-ichi Hirano Osaka University

# *The Third International Symposium on NLSD/TGCV*

11:00-15:00, March 14, 2015

## **Preliminary program**

**Opening remark:** Ken-ichi Hirano, Oaska, Japan

### **Oral presentation (1) ☉ 11:00-12:00**

12 min presentation, 3 min discussion

**Chairpersons:** Kunihisu Kobayashi, Fukuoka, Japan  
Masanori Fukushima, Kobe, Japan

- O-1 Regulatory factors in neutral lipid storage myopathies (LSM) with triglyceride accumulation  
**Corrado Angelini, Venice, Italy**
- O-2 A review of Neutral lipid storage disease with myopathy in mainland China  
**Yun Yuan, Beijing, China**
- O-3 Late onset and heterogeneous clinical presentation in three affected members of a NLSDM Italian family  
**Daniela Tavian, Milan, Italy**
- O-4 Triglyceride deposit cardiomyovasculopathy with and without genetic mutations in the adipose triglyceride lipase  
**Ken-ichi Hirano, Osaka, Japan**

### **Oral presentation (2) ☉ 12:00-12:40**

7 min presentation, 3 min discussion

**Chairpersons:** Shu-Ping Hui, Sapporo, Japan  
Ken-ichi Hirano, Osaka, Japan

- O-5 Italian Registry of NLSDs. Genetical and clinical characterization  
**Elena Pennisi, Rome, Italy**
- O-6 Quantification of plasma capric acid concentration using high-performance liquid chromatography  
**Rojeet Shresta, Sapporo, Japan**
- O-7 Depletion of ATGL Exacerbates Cuff Injury-Induced Vascular Remodeling by Enhancing Adventitial Inflammation  
**Sohsuke Yamada, Kitakyushu, Japan**
- O-8 The world smallest Microminipigs, a novel atherosclerosis-prone miniature pigs: its characteristics and perspectives  
**Akhide Tanimoto, Kagoshima, Japan**

### **Poster presentation ☉ 13:00-15:00**

**Free discussion in any languages with sandwiches and drinks**

**Moderators:** Hiroshi Nakamura, Yamaguchi, Japan  
Daniela Tavian, Milan, Italy,

**Discussants:** Toshihide Kobayashi, Saitama  
Yun Yuan, Beijing, China

#### **Diagnosis for NLSD/TGCV**

- P-1 Development of human adipose triglyceride lipase (ATGL) specific measurement system: production of rabbit anti-human ATGL antibody neutralizing ATGL activity  
**Atsuko Takagi, Suita, Japan**
- P-2 Histological Validation of Thin-Cap Fibroatheromas by Intravascular Imaging: The Basic Study for Diagnosis of Coronary Triglyceride Deposition  
**Hiroyuki Hao, Hyogo, Japan**

- P-3 Rapid screening of Jordans' anomaly using Pentra MS CRP automated hematology analyzer  
**Tohru Inaba, Kyoto, Japan**
- P-4 Jordans' anomaly in triglyceride deposit cardiomyovasculopathy  
**Sachiko Ezoe, Osaka, Japan**
- P-5 Lipid droplets in peripheral leukocytes of TGCV patients are detected with an automated hematology analyzer XE-5000  
**Atsushi Wada, Hyogo, Japan**

#### *Analysis for NLSD/TGCV*

- P-6 Quantitative proteomic analysis of hearts from adipose triglyceride lipase knockout mice  
**Yasuhiro Hara, Suita, Japan**
- P-7 Biodistribution of C-11 labelled middle chain fatty acids in normal mice  
**Yasuhiro Magata, Shizuoka, Japan**
- P-8 Nonlinear Raman imaging to trace the lipid in cells using deuterated lipid  
**Mamoru Hashimoto, Osaka, Japan**
- P-9 Visualization of cholesterol ester in formaldehyde-fixed coronary artery  
**Nobuhiro Zaima, Nara, Japan**

#### *Medium chain fatty acids for NLSD/TGCV*

- P-10 Triglyceride Deposit Cardiomyovasculopathy with Severe Heart Failure  
**Koichiro Sugimura, Miyagi, Japan**
- P-11 Nutritional management and evaluation for a patient with triglyceride deposit cardiomyovasculopathy/neutral lipid storage disease with myopathy (NLSD-M)  
**Yoko Yasui, Osaka, Japan**
- P-12 An experience of dietary therapy with medium chain fatty acids in a patient with adipose triglyceride lipase deficiency living in a rural village in the Tohoku district, Japan  
**Ken-ichi Hirano, Osaka, Japan**
- P-13 Nonclinical toxicology and safety pharmacology of CNT-01  
**Sachiko Tajima, Tokyo, Japan**

#### *Animal Models for NLSD/TGCV*

- P-14 Effects of CNT-01 on the Production of Lipids and Lipoproteins from the Small Intestine in Mice  
**Bo Zhang, Fukuoka, Japan**
- P-15 Effect of CNT-01-containing diet on adipose triglyceride lipase KO mice.  
**Akira Suzuki, Osaka, Japan**
- P-16 Development of Diabetes Mellitus Model in Novel Microminipig  
**Hiroaki Kawaguchi, Kagoshima, Japan**

#### *Case reports with NLSD/TGCV and related disorders*

- P-17 Muscle MRI in neutral lipid storage disease with myopathy  
**Chunxiao Xu, Beijing, China**
- P-18 Chanarin-Dorfman syndrome: a case report with novel mutation in ABHD5 gene  
**Sara Missaglia, Milan, Italy**
- P-19 A case of a diabetic patient with suspected TGCV  
**Junji Kozawa, Osaka, Japan**
- P-20 Diagnosis of lysosome disease using ultrastructural examination  
**Tetsuhiko Yasuno, Fukuoka, Japan**

### **Steering committee meeting ☉ 15:00-16:00**

**Secretary Yoshihiko Ikeda, Osaka, Japan**

1. Introduction of new members ..... **Shu-Ping Hui, Sapporo, Japan**
2. Development of CNT-01.....**Ken-ichi Hirano, Osaka, Japan**
3. Publication policy and global collaboration for the international registry for NLSD/TGCV
4. Discussion for the announcement for the Third International Symposium